JP2021535110A5 - - Google Patents

Info

Publication number
JP2021535110A5
JP2021535110A5 JP2021509758A JP2021509758A JP2021535110A5 JP 2021535110 A5 JP2021535110 A5 JP 2021535110A5 JP 2021509758 A JP2021509758 A JP 2021509758A JP 2021509758 A JP2021509758 A JP 2021509758A JP 2021535110 A5 JP2021535110 A5 JP 2021535110A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
alkyl
composition according
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021509758A
Other languages
English (en)
Japanese (ja)
Other versions
JP7590083B2 (ja
JP2021535110A (ja
Filing date
Publication date
Priority claimed from GBGB1814207.5A external-priority patent/GB201814207D0/en
Priority claimed from GBGB1908225.4A external-priority patent/GB201908225D0/en
Application filed filed Critical
Priority claimed from PCT/EP2019/073212 external-priority patent/WO2020043878A1/en
Publication of JP2021535110A publication Critical patent/JP2021535110A/ja
Publication of JP2021535110A5 publication Critical patent/JP2021535110A5/ja
Application granted granted Critical
Publication of JP7590083B2 publication Critical patent/JP7590083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509758A 2018-08-31 2019-08-30 併用療法 Active JP7590083B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1814207.5 2018-08-31
GBGB1814207.5A GB201814207D0 (en) 2018-08-31 2018-08-31 Combination Therapy
GBGB1908225.4A GB201908225D0 (en) 2019-06-10 2019-06-10 Combination therapy
GB1908225.4 2019-06-10
PCT/EP2019/073212 WO2020043878A1 (en) 2018-08-31 2019-08-30 Combination therapy

Publications (3)

Publication Number Publication Date
JP2021535110A JP2021535110A (ja) 2021-12-16
JP2021535110A5 true JP2021535110A5 (enExample) 2022-08-29
JP7590083B2 JP7590083B2 (ja) 2024-11-26

Family

ID=67841060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509758A Active JP7590083B2 (ja) 2018-08-31 2019-08-30 併用療法

Country Status (16)

Country Link
US (1) US20210322564A1 (enExample)
EP (1) EP3843748B1 (enExample)
JP (1) JP7590083B2 (enExample)
KR (1) KR20210054520A (enExample)
CN (1) CN112638392B (enExample)
AU (1) AU2019332979B2 (enExample)
BR (1) BR112021003675A2 (enExample)
CA (1) CA3107085A1 (enExample)
ES (1) ES3037206T3 (enExample)
IL (1) IL280968B2 (enExample)
MX (1) MX2021001908A (enExample)
PH (1) PH12021550376A1 (enExample)
SG (1) SG11202101518QA (enExample)
UA (1) UA128954C2 (enExample)
WO (1) WO2020043878A1 (enExample)
ZA (1) ZA202100467B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020292965A1 (en) * 2019-06-10 2022-01-27 Adc Therapeutics Sa Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or a secondary agent
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
EP4362983A1 (en) * 2021-06-29 2024-05-08 ADC Therapeutics SA Combination therapy using antibody-drug conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
JP6392765B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa ピロロベンゾジアゼピン−抗体結合体
HRP20182129T1 (hr) * 2012-10-12 2019-02-08 Adc Therapeutics Sa Konjugati protutijelo - pirolobenzodiazepin
GB201506399D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
WO2017160954A1 (en) * 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
US12358983B2 (en) * 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
EP3612839A1 (en) * 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy
CA3064804A1 (en) * 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc

Similar Documents

Publication Publication Date Title
JP2021524449A5 (enExample)
JP2021535110A5 (enExample)
JP2024514339A5 (enExample)
JP2018502902A5 (enExample)
JP2022535609A5 (enExample)
JP2023036950A (ja) 癌治療のための組み合わせ療法
JP5785157B2 (ja) Plk1阻害剤および抗腫瘍剤を含む治療組合せ
HRP20171727T1 (hr) Novi terapeutici
JP2018516243A5 (enExample)
HRP20181646T2 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
JP2016508130A5 (enExample)
FI3988117T3 (fi) Terapeuttiset vasta-aineet ja niiden käyttö
JP2019506403A5 (enExample)
JP2020505433A5 (enExample)
NZ710745A (en) Pyrrolobenzodiazepines and conjugates thereof
JP2019501204A5 (enExample)
JP2014510729A5 (enExample)
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
JP2017502994A5 (enExample)
HRP20180945T1 (hr) Konjugati protutijelo-pirolobenzodiazepin
JP2013518086A5 (enExample)
JP2022523740A5 (enExample)
JP2021530444A5 (enExample)
JP2018525358A5 (enExample)
JP2010523696A5 (enExample)